Brief: Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

Senti Biosciences Holdings

13/05/2024 13:19

May 13 (Reuters) - Senti Biosciences Inc  SNTI.O :
    * SENTI BIO ANNOUNCES FIRST PATIENT DOSED IN PHASE 1
CLINICAL
TRIAL OF SENTI-202 FOR THE TREATMENT OF RELAPSED OR REFRACTORY
HEMATOLOGIC MALIGNANCIES INCLUDING ACUTE MYELOID LEUKEMIA
    * SENTI BIOSCIENCES INC: INITIAL CLINICAL EFFICACY DATA
EXPECTED
BY YEAR-END 2024 AND DURABILITY DATA EXPECTED IN 2025
    * SENTI BIOSCIENCES INC - INITIAL CLINICAL EFFICACY DATA
EXPECTED
BY YEAR-END 2024 AND DURABILITY DATA EXPECTED IN 2025

Source text for Eikon:  ID:nGNX7TWFM4 
Further company coverage:  SNTI.O 

 ((Reuters.Briefs@thomsonreuters.com;))